JOSELYN RWEBEMBERA
ID: UNCST-2021-R013915
|
A Non-Inferiority Trial of Stopping Penicillin in Early Rheumatic Heart Disease: GOAL-Stop
REFNo: HS6744ES
To explore if risk of progression differs between children who initially received 2 years of oral SAP as compared to 2 years of intramuscular SAP during the GOALIE trial. ,To determine in children with previously diagnosed mild RHD and echocardiographic stabilization after receiving SAP for at least 2 years, if stopping secondary antibiotic prophylaxis (SAP) is non-inferior to continuing SAP in preventing progression over the next 2 years. ,To determine in children with previously diagnosed mild RHD and echocardiographic normalization after receiving SAP for at least 2 years, if stopping SAP is non-inferior to continuing SAP for preventing progression over the next 2 years. ,To determine in children with previously diagnosed mild RHD and echocardiographic normalization or echocardiographic stability after receiving SAP for at least 2 years, if stopping SAP is non-inferior to continuing SAP for preventing progression by 4 years (2 years after SAP discontinuation). ,
|
|
Uganda |
2025-12-18 18:47:07 |
2028-12-18 |
992 |
Children and adolescents will be eligible for study participation if they (1) participated in the GOALIE Trial, (2) are found to have echocardiographic normalization or stable mild RHD at study completion, (3) are between the ages of 5-20 years at the time of enrollment. |
Thrasher Research Fund & Open Philanthropy |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Pauline Byakika-Kibwika
ID: UNCST-2019-R001206
|
A phase III, multi-country, randomized, placebo-controlled, double-blinded adaptive platform trial to assess the efficacy and safety of treatments for participants with Mpox virus disease
REFNo: HS6913ES
To evaluate the safety and efficacy, as assessed by mortality, hospitalization, complications, duration of symptoms of IP + SOC compared to placebo + SOC in participants with Mpox.,The primary objective is to evaluate the clinical efficacy, as assessed by time to lesion(s) resolution, of IP + Standard of Care (SOC) compared to placebo + SOC for participants with Mpox.,
|
Wakiso, kisubi
Mbarara, Mbarara
|
Uganda |
2025-12-18 18:34:19 |
2028-12-18 |
422 |
Participants fulfilling all the following inclusion criteria are eligible for the study:
1. Signed informed consent or assent for minor participants
2. Adults with positive mpox virus PCR confirmed within 7 days of D1and at least one
skin lesion:
- with known self-reported HIV positive with or without mucosal lesions
- Or
- Self-reported HIV negative or unknown HIV status with mucosal lesions
3. Children with positive mpox virus PCR confirmed within 7 days of D1 and at least
one skin lesion
4. Newborns with positive mpox virus PCR confirmed within 7 days of D1 and at least
one skin lesion
5. Specific to the BCV arm and matching placebo-Women participants of childbearing
potential willing to use condoms during treatment and for at least 2 months after the
last dose of BCV.
6. Specific to the BCV arm and matching placebo-Male participants with partners of
childbearing potential willing to use condoms during treatment and for at least 4
months after the last dose of BCV.
i. To protect women of a potential teratogenic treatment
ii. and anyhow for MSM (men who have sex with men to avoid sexual
transmission |
PANdemic Preparedness Platform for Health and Emerging Infections’ Response (PANTHER) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Pauline Amuge Mary
ID: UNCST-2023-R005532
|
Bedaquiline Roll-out Evidence in Contacts and People
Living with HIV to prevent TB
(BREACH-TB)
REFNo: HS6975ES
2.1.1.To estimate the safety of 1BDQ and 3HP among
adult, adolescent, and child CCs of DS-TB Index
Patients at high risk of developing TBD, as well
as adult and adolescent PLHIV in high TB burden settings
2.1.2To estimate the safety of 1BDQ and 6 months of
levofloxacin (LFX) among adult, adolescent, and
child CCs of RR-TB Index Patients at high risk of
developing TBD
2.1.3 To estimate on-time treatment completion of
1BDQ and 3HP among adult, adolescent, and
child CCs of DS-TB Index Patients at high risk of
developing TBD, as well as adult and adolescent
PLHIV in high TB-burden settings
2.1.4To estimate on-time treatment completion of
1BDQ and 6 months of levofloxacin (LFX)
among adult, adolescent, and child CCs of RRTB Index Patients at high risk of developing TBD
|
Wakiso, Ssabagabo
|
Uganda |
2026-02-05 22:05:22 |
2029-02-05 |
3130 |
High-risk close contacts (CC) of an individual diagnosed with DS- or RR-TBD
(i.e., the Index Patient) and PLHIV in high-TB burden regions |
United States Agency for International Development |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Victoria Nankabirwa
ID: UNCST-2021-R011871
|
Relaxation Intervention to Improve Newborn Growth and Maternal Well-being
REFNo: HS6916ES
To examine the effect of the APRB on maternal outcomes such as stress, anxiety and depression.,To evaluate the effect of the adapted APRB on infant outcomes such as growth, feeding and adverse events.,To develop and adapt an audiorecording promoting relaxation during breastfeeding (APRB) for use among postpartum mothers Uganda.,
|
|
Uganda |
2026-01-19 15:24:38 |
2029-01-19 |
136 |
Adult women (18 years and above) and their infants.All sexes and tribes are eligible |
US National Institutes of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
.jpg)
|
Dennis Muhanguzi
ID: UNCST-2019-R001101
|
Evaluation of The Safety, Efficacy and Stability of Sangaphos® Emulsifiable Concentrate [E.C]: A Randomised Single-Blinded Positive Controlled Multi-Site Acaricide Field Trial
REFNo: NS1171ES
General objectives:
To determine the efficacy, safety, and stability of SangaPhos [Sanga Vet. Chem. Ltd, Kampala Industrial Park, Namanve] when applied onto cattle by hand spraying and plunge dipping for tick control.
Specific objectives
The specific objectives of this acaricide field trial will to determine;
i.Efficacy of Sangaphos® when applied onto cattle by hand spraying and plunge dipping for tick control.
ii.Safety of Sangaphos® when applied onto cattle by hand spraying and plunge dipping for tick control.
iii.Stability of Sangaphos® when applied onto cattle by plunge dipping for tick control.
|
Kyenjojo, Ntuutu
Kyenjojo, Bwenzi
Kyenjojo, Hima
Serere, Aarapoo
Serere, Aswii
Kumi, Kachaboi
|
Uganda |
2026-03-03 12:23:56 |
2029-03-03 |
633 |
Six Cattle farms from Kyenjojo [n=3], Kumi [n=01] and Serere each with at least 66 cattle will be recruited. Total number of cattle at the six farms = 633. The animals will be at least 2 months of age. Both sexes and any cattle breeds on these farms will be recruited. |
Sanga Vet. Chem. Ltd P.O Box 75164 | Plot 1144, Kampala Industrial Business Park | Kampala-Uganda Tel: 02008000100 | Web: https://www.sangavetchem.com/ |
Natural Sciences |
Clinical Trial |
Non-degree Award |
|
Catriona Waitt John
ID: UNCST-2019-R001068
|
Implementation of a "bundle of care" to improve anticoagulation control in patients receiving warfarin in Uganda and South Africa
REFNo: HS1422ES
Primary objective is to evaluate whether implementation of warfarin bundle improves time in therapeutic range
Secondary objectives are:
-To evaluate whether implementation of the warfarin bundle improves time to achieving a therapeutic INR
-Whether implementation of the warfarin bundle affects the occurrence of adverse events(death, bleeding and thrombotic events)
-whether staff find the interventions contained in the bundle acceptable
-To explore patients' experiences and acceptability of the package of care, and
-Whether the bundle represents good value for money
|
Kampala, Salaama
Kampala, Mulago
|
UK |
2021-07-09 |
2024-07-09 |
444 |
Adult patients (18 years or older),male or female newly initiated on warfarin for the first time |
University of Liverpool |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Jayne Ellis
ID: UNCST-2021-R013987
|
“Integrated management of cryptococcal and opportunistic infections to improve outcomes in advanced HIV disease (IMPROVE study)â€
REFNo: HS1607ES
1) To generate evidence on the safety (adverse events) and feasibility (adherence and tolerability) of 1HP (one month of isoniazid and rifapentine) for TB preventative therapy (TPT) amongst adults with HIV-associated cryptococcal meningitis.
2) To generate preliminary data on potential secondary benefits (reduced loss to follow-up, reduced active TB disease, reduced mortality due to TB) of early (inpatient initiation) 1HP TPT as compared to standard (outpatient initiation) 1HP TPT amongst adults with HIV-associated cryptococcal meningitis.
|
Kampala, Salaama
Mbarara, Mbarara
|
UK |
2021-08-25 |
2024-08-25 |
205 |
Adults (>18 years) with HIV-associated cryptococcal meningitis |
London School Hygiene and Tropical Medicine |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Raymond Tweheyo
ID: UNCST-2020-R014507
|
Evaluating the pilot of the Community Health Extension Worker (CHEW) strategy in Uganda: assessing feasibility, and effectiveness for improving Village Health Team (VHT) supervision and reporting
REFNo: HS2545ES
General Objective
To explore the acceptability, document the implementation process and evaluate the effectiveness of the Community Health Extension Worker strategy in two districts of Uganda to guide improving the community health system
Specific Objectives
1) To assess the acceptability of introducing a Community Health Extension Worker (CHEW) strategy in a district health system.
2)To document the process of setting up and implementing a Community Health Extension
Worker (CHEW) strategy within a district health system.
3) To estimate the program costs and duration for setting up a government-led Community Health Extension Worker (CHEW) strategy within a district health system.
4) To determine the effectiveness of the CHEW strategy for improving the quality of Village Health Team (VHT) member’s supervision and reporting in a district health system.
5) To assess the effect of the CHEW strategy on community-level indicators: completion of four antenatal care visits, skilled delivery attendance, fully immunized under-fives, and U5 sick children seen by VHTs and treated within 24 hours.
|
Mayuge, all parishes
Lira, all parishes
Kabarole, all parishes
Kyotera, all parishes
|
UK |
2023-01-03 13:08:01 |
2026-01-03 |
3,016 women of reproductive age |
1) Household members: Adult women of reproductive age 18 to 49 years.
2) Community health workers - 18 years and above
3) Health facility workers - 18 years and above
4) District technical and political leaders - 18 years and above
5) Community Health Implementing partners - adults, 18 years and above |
USAID/ Uganda Health Systems Strengthening Activity (UHSS) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Kathy Burgoine
ID: UNCST-2022-R011521
|
Impact of prophylactic Continuous Positive Airway Pressure in the Delivery Room (DR-CPAP) on neonates <1500g in a low-resource setting: A feasibility trial
REFNo: HS2605ES
- To determine the acceptability of DR-CPAP to healthcare workers in a low-resource setting
- To determine the post-intervention acceptability of using a two-stage consent process in neonatal emergencies in the delivery room in this setting
- To evaluate the feasibility of a third-party allocation process for randomisation by determining the time to randomization
- To evaluate feasibility of initiating DR-CPAP in a low-resource setting in infants with birthweight 800-1500g within 15 minutes of delivery
- To determine the safety of initiating DR-CPAP in a low-resource setting
- To estimate the sample size to be used for future evaluation in the full trial
- To assess the feasibility of secondary outcome measures to be used in the full trial
|
Mbale,
|
UK |
2023-02-02 12:18:23 |
2026-02-02 |
100 |
The study population will be inborn preterm infants with a birthweight of 800g to less than 1500g who are spontaneously breathing at 5 minutes of life. They will be recruited within 15 minutes of birth and followed up until death or 28 days. Both male and female infants will be included. |
Mbale Clinical Research Institute (MCRI) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Raymond Tweheyo
ID: UNCST-2020-R014507
|
Understanding the effect of varied financial compensation structure for improving the performance, motivation and retention of Community Health Workers in Uganda - a quasi experiment
REFNo: HS2689ES
General objective: To understand the effect of varied financial compensation structure for improving the performance, motivation and retention of Community Health Workers in Uganda.
Specific objectives:
1. To determine the optimal performance based financial incentive incentive's structure required for improving the performance, motivation and retention of CHWs.
2. To explore the acceptability and perceptions of potential sustainability of CHWs financial compensation structure to various stakeholders, including the CHWs, and the CHW supervisors at the district and Ministry of Health.
3. To explore the perceived value and impact of financial incentives on CHW's job satisfaction, personal income and livelihood.
|
Wakiso, all parishes
Mpigi, all parishes
Mbale, all parishes
Jinja, all parishes
|
UK |
2023-03-07 10:40:31 |
2026-03-07 |
3,215 children under five, 720 Community Health Workers, 32 Key Informants |
1. Women of reproductive age (18 to 49 years) who have a child under five years of age.
2. Community Health Workers (18 years and above)
3. Adult Key Informants - district, Ministry of Health and Implementing Partner officials |
USAID/ Living Goods |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Moses Oketch
ID: UNCST-2024-R004313
|
Long-Term Impacts of Improved Childhood Literacy
REFNo: SS2796ES
Economic situation,
|
Amolatar,
Dokolo,
|
UK |
2024-08-05 14:01:33 |
2027-08-05 |
6581 |
Former participants of a study on the impact of an early-grade literacy intervention. The study was implemented from 2009 to 2011. The respondents are aged between 19 and 24 years old, with an average age of 21 years. |
Center for Global Development |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
Catriona Waitt John
ID: UNCST-2019-R001068
|
Drug Optimisation for LMICs in Pregnant HIV mothers and their INfants: temporary switch to CAB/RPV long acting injections in postpartum period
REFNo: HS5982ES
To characterise drug exposure in breast milk, and drug transfer to infants through breastfeeding, as well as infant drug elimination.
To characterise the elimination of CAB/RPV by describing PK profiles of IM CAB/RPV LA after last injection between 48 and 96 weeks.
To establish strategies on how to safely re-establish oral ART after discontinuation of IM CAB/RPV LA at 48 weeks and switch back to daily oral ART.
To explore early postpartum PK of CAB/RPV in maternal plasma and breastmilk.
To demonstrate antiviral activity and impact on retention in HIV care of temporarily switching to CAB/RPV LA compared with continuation of daily oral ART over 48 weeks.,
|
Kampala, Kampala
|
UK |
2025-09-17 13:21:16 |
2028-09-17 |
309 |
Consenting pregnant women living with HIV |
University of CapeTown |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Lisa Hartwig
ID:
|
The effectiveness of a behavioral science and design intervention for family savings on increased use of maternal health services and male involvement: a randomized controlled trial
REFNo: HS2194ES
To assess the effectiveness of a behavioral intervention designed to encourage financial savings for healthcare costs and birth preparedness among pregnant women and their partners in Uganda. To examine whether increased earmarked financial savings for healthcare costs leads to increased utilization of maternal health services and male involvement in maternal healthcare.
|
Kyotera, All
|
USA |
2022-05-23 9:28:49 |
2025-05-23 |
700 |
To be eligible for joining the study, the participants must fulfill the following eligibility criteria: (1) 18-49 years old, (2) Between 12-32 gestational weeks (pregnant female) OR partner of someone who is (male), (3) Own a mobile phone, (4) Has a regis |
The University of Tokyo |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Thomas McHale
ID: UNCST-2022-R008812
|
Optimizing the Dose of Flucytosine for Cryptococcal Meningitis
REFNo: HS2940ES
Determine if 50 mg/kg/day of 5-FC has a similar mortality benefit compared to 100 mg/kg/day,Reduce the cost and supply burden of treating an individual with cryptococcal meningitis,Determine if 50 mg/kg/day of 5-FC is a safer dosage compared to 100 mg/kg/day of 5-FC,Determine if 50 mg/kg/day of 5-FC is has a similar rate of cryptococcal clearance from CSF compared to 100 mg/kg/day,Determine the optimal dose of 5-FC for for management of induction phase of therapy for cryptococcal meningitis,
|
Kampala,
Mbarara,
|
USA |
2023-07-05 11:41:24 |
2026-07-05 |
The target sample size is 50 participants |
The study will enroll adults with HIV who are over 18 years old and sick with cryptococcal meningitis. |
National Institute of Health, United States |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Sarah Lofgren
ID: UNCST-2019-R001647
|
Supervised Treadmill intervention to Reduce Inflammation and Depression through Exercise in HIV: The STRIDE Pilot Study
REFNo: HS3358ES
The objective of this study is to determine the feasibility and acceptability of an aerobic intervention via a treadmill among individuals with HIV and depression in Uganda.
3.1 Primary Endpoint: Feasibility and acceptability of Exercise as a treatment for depression in Ugandans with HIV. This will be measured by:
-Percent completion of the prescribed aerobic exercise intervention, as assessed by research staff logging participation.
3.2 Secondary Endpoint(s)/ Outcome(s):
- acceptability of the intervention assessed via a post intervention survey
-feasibility and acceptability of using a wearable exercise tracker to assess the volume of exercise, based on calories burned and steps achieved, during the intervention period among Ugandans with HIV and depression.
- measure the mean and standard deviation of baseline and 8-week serum BDNF and IL-6 level to estimate an effect size and power a future study.
- measure the mean and standard deviation of baseline and 8-week depression score via PHQ-9 to estimate an effect size and power a future study.
- measure the mean and standard deviation in aerobic fitness baseline and at 8 weeks measured via METS/watts achieved and total time/distance to estimate the effect size for a future intervention.
|
Wakiso, Lweeza
|
USA |
2024-02-26 13:41:23 |
2027-02-26 |
24 |
• Enrolled in Mildmay HIV clinic
• Adults 18-45 years old
• HIV positive
• Receiving HIV therapy
• HIV viral suppression (<400 copies/mL) per chart review
• Mild to Moderate (PHQ9 score >5 but >20)
• Not currently engaged in a formal exercise program or manual labor such as construction or delivery requiring a manual bike or walking
• Able to walk/run on a treadmill
• Informed consent
|
University of Minnesota, Makerere University |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Schola Matovu Nakachwa
ID: UNCST-2022-R011040
|
Development and Testing of BAJJAJJA: An Intervention to Promote Economic Empowerment and Health of Grandmothers who Provide Primary Care for Grandchildren in Uganda
REFNo: SS3611ES
Main Objective
The study’s objective is to refine and test the feasibility and acceptability of my innovative intervention, BAJJAJJA: Building A Joint Action for JaJJAs which couples an income- generating activity (IGA) with nurse-facilitated group health coaching. This objective is informed by the NIH Stage Model of behavioral intervention development.
Specific Objectives
Aim 1: To refine and adapt the BAJJAJJA intervention through a collaborative and iterative feedback process with a diverse community group of 18 members. In a series of sessions, I will iteratively engage diverse community groups (nurses, local officials, IGA experts, and GMCs) and use cognitive interviewing to gain feedback on the appropriateness of study measures, content, delivery, and intervention format.
Aim 2: To test the feasibility, acceptability, and preliminary efficacy of the BAJJAJJA intervention in improving economic and health outcomes among 24 Ugandan GMCs. Over a 12-month period and at three time points of assessment, I will use a mixed methodology with a quasi-experimental design to collect data that will be examined to assess the feasibility, acceptability, and preliminary efficacy of the intervention on participants’ household income and health outcomes.
Aim 3: To explore the barriers and facilitators to (3a) maintenance of the BAJJAJJA individual intervention benefits (e.g., physical activity level and frequency) and (3b) sustainability of the IGA activities (e.g., grandmothers’ accessing external supports such as community resources) at 6 months post-intervention. Following a mixed methods approach, the 24 GMCs from Aim 2 will be interviewed to further evaluate the long-term maintenance and sustainability of the intervention. Health assessments, interviews, and IGA site visits will be used to explore the intervention outcomes and benefits at 6 months post-intervention.
|
Buikwe, Kiteza
|
USA |
2025-03-10 12:23:29 |
2028-03-10 |
24 Grandmother Caregivers |
1. Grandmothers:
Ugandan GMCs who are (a) > 50 years (considering the average reproductive age range in Uganda of 15-49 years), (b) Luganda-speaking (commonly spoken language), (c) primary caregivers for at least one minor grandchild (< 18 years) for > 6 months, and (d) able to perform activities of daily living (e.g., cooking, bathing) without assistance.
2.Community Advisory Board:
10 key informants: Local elected community leaders ( LCs), healthcare professionals, nurses from local health centers and a village health team member, IGA experts, and grandmothers. Participants will be identified by LC leaders or referred by other participants using a snowball sampling technique.
Participants are female (grandmother caregivers) with no tribal restrictions as long as she can speak luganda
|
NIH JOHN E FORGATY International Center |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
Isabelle Cohen
ID: UNCST-2025-R020977
|
Evaluating a “nearly free hour” for health centers in rural Uganda
REFNo: SS4726ES
This study has four specific objectives:
1. Evaluate the effects of a discounted, group visits window on ODH health centers, including how many ultrapoor patients visit the clinic during the discounted, group visits window.
2. Compare the discounted window to an all-day discount to understand whether a time-limited discount is (relatively) more effective at screening in the UP.
3. Document the extent to which the discounted window cannibalizes revenue by shifting patients from other times of day to the discounted window.
4. Analyze whether discounts encourage earlier treatment for mild/moderate malaria, and correspondingly reduce visits for severe malaria.
|
|
USA |
2026-01-27 19:41:22 |
2029-01-27 |
25000 |
The total set of districts includes ADJUMANI, AGAGO, ALEBTONG, AMOLATAR, AMURIA, AMURU, APAC, DOKOLO, GULU, KADERAMAIDO, KAGADI, KAKUMIRO, KASSANDA, KATAKWI, KIBAALE, KIKUUBE, KITGUM, KOLE, KUMI, KWANIA, LIRA, MASINDI, MUBENDE, NWOYA, OMORO, OTUKE, OYAM, PADER and SERERE.
The study sample focuses on villages in the catchment areas of existing ODH health clinics. We include villages that are not health clinic locations, from which more than a minimum number of patients visit ODH health clinics in an average week. We expect to sample roughly six villages per health clinic. All patients from a participating village who visit an ODH clinic included in the study will be considered part of the study.
|
Weiss Fund for Research in Development Economics, Princeton University’s Research Program in Development Economics and OneDay Health |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|
